Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (OACC)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I see a blank-check shell, not an operating business. Oaktree Acquisition Corp. III Life Sciences has no significant operations; it is a pool of capital hunting for a merger in biopharma, medical devices, diagnostics, or specialized healthcare services. The filed figures show no revenue in any period. For FY2025, period ended 2025-12-31, net income was $7.3 million; fiscal Q2 2026, quarter ended 2026-06-30, net income was $1.6 million; fiscal Q1 2026, quarter ended 2026-03-31, was $1.4 million; fiscal Q3 2025, quarter ended 2025-09-30, was $2.0 million; and fiscal Q2 2025, quarter ended 2025-06-30, was $1.9 million. Those profits are not from selling products or services. Trailing free cash flow was negative $455,689. At the 2026-10-13 close of $10.75, FairStock calculates a P/E of 38.39, a Graham Number of $7.12, and a margin of safety of negative 50.98%. The Piotroski F-Score is 2/9, Altman Z-Score is 17.95, and the FairStock Score is 36/100. There is no competitive moat, because there is no business yet. Graham would ask about asset protection; Buffett would ask about durable economics. Here, both answers depend almost entirely on the yet-to-be-announced acquisition. Until then, the stock trades mostly on deal hope and trust-account math, not on operating performance.

In plain English: Oaktree Acquisition Corp. III Life Sciences is a shell company. It has no real business operations and is looking to merge with a healthcare company. Its recent filings show no revenue, small net income, and cash used in operations. The stock trades near $10.75, which looks expensive compared with the accounting value shown, but this kind of company is really a bet on a future merger.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer